News
FDA aims for Tlando decision for testosterone replacement therapy in week of 7 December 2020.- Lipocine
Lipocine Inc. announced that the FDA has informed the Company that it is continuing to work towards taking action on the Tlando New Drug Application ("NDA") for testosterone replacement therapy during the week of December 7, 2020. However, the Company cannot assure that the FDA will act in that time frame.
Condition: Testosterone Deficiency
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.